reports
Elior Group: 1 director
A director at Elior Group bought 10,000 shares at 2.750EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Ageas reports on the progress of share buy-back programme
Ageas reports on the progress of share buy-back programme Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 52,761 Ageas shares in the period from 18-11-2024 until 22-11-2024. DateNumber ofSharesTotal amount(EUR)Average price(EUR)Lowest price(EUR)Highest price(EUR)18-11-20245,178251,96048.6648.5248.8219-11-20249,691466,81948.1747.8648.9020-11-20248,970435,89948.6048.4648.8021-11-202419,250931,77148.4048.1448.5222-11-20249,672469,64248.5648.3048.76Total52,7612,556,09...
Ageas rapporteert over de inkoop van eigen aandelen
Ageas rapporteert over de inkoop van eigen aandelen Ageas rapporteert over de inkoop van eigen aandelen Naar aanleiding van het aandelen-inkoopprogramma dat op 28 augustus 2024 aangekondigd werd, maakt Ageas bekend dat er 52.761 eigen aandelen ingekocht werden tussen 18-11-2024 en 22-11-2024. DatumAantalaandelenTotaal Bedrag(EUR)Gemiddelde koers(EUR)Laagste koers(EUR)Hoogste koers(EUR)18-11-20245.178251.96048,6648,5248,8219-11-20249.691466.81948,1747,8648,9020-11-20248.970435.89948,6048,4648,8021-11-202419.250931.77148,4048,1448,5222-11-20249.672469.64248,5648,3048,76Totaal52.7612.556.0904...
- Research Department
INFORME DIARIO 25 NOVIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CELLNEX. EUROPA: UNICREDIT, VINCI. Otra semana más con EE.UU. haciéndolo mejor Una semana más EE.UU. cierra en positivo mientras Asia registró caídas y Europa terminó con signo mixto donde el FTSE y el SMI fueron los mejores y el CAC y MIB los peores. Dentro del STOXX 600, Media y Farma lideraron las ganancias mientras que los Bancos fueron los que más cayeron (>-2,0%), seguidos de Viajes&Ocio y Autos. Por el lado macro, Eurozona los PMIs prelimin...
- Research Department
IBERIAN DAILY 25 NOVEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: CELLNEX. Another week with the US leading the way It was another week with the US closing in positive numbers, whereas Asia saw losses and Europe ended with mixed performance, where the FTSE and SMI were the best performers and the CAC and MIB the worst. In the STOXX 600, Media and Pharma led the gains, while Banks saw the biggest drops (more than -2.0%), followed by Travel & Leisure and Autos. On the macro side, in the euro zone November’s preliminary manufacturing and services P...
Lagardere S.A.: 1 director
A director at Lagardere S.A. bought 1,403 shares at 20.500EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- Carole Braudeau
- Emmanuel Matot
- Carole Braudeau
- Emmanuel Matot
- Research Department
IBERIAN DAILY 21 NOVEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: SANTANDER. Caution continues due to the geopolitical situation European stock markets ended with slight corrections despite the initial gains, with all eyes on the tension in Ukraine and Nvidia’s results (that released good earnings after the closing bell). Thus, in the STOXX 600, Basic Resources and Pharma (for the second consecutive session) led gains vs. Automobiles (once more the worst performer) and Real Estate that ended with the biggest drops. From the ECB, L. de Guindos c...
- Johanna Jourdain
Elior : Very negative market reaction to FY 2023-24 results publicatio...
>FY 2023-24 publication confirms operational progress despite higher than expected tax burden - Yesterday, Elior released its 2023-24 results before the market open. EBIT was 3% above expectations (margin of 2.8%, i.e. +170 bp) but reported net profit was significantly lower (loss of € 41m vs consensus of +€ 7m). This is mainly due to a higher-than-expected tax charge (€ 36m in 20223-24, reflecting higher taxable profits in France, vs € 29m in 2023, which benefited fr...
- Johanna Jourdain
Elior : Publication lourdement sanctionnée malgré des progrès opératio...
>Publication FY 24 qui confirme les progrès opérationnels malgré un poids des impôts plus important qu’attendu - Elior a publié hier avant Bourse des résultats 2024 qui sont ressortis 3% au-dessus des attentes au niveau de l’EBIT (marge à 2.8% soit +170 pb) mais très significativement inférieurs au niveau du résultat net publié (perte de 41 M€ vs consensus à +7 M€). Ceci est principalement dû à une charge d’impôts supérieure aux attentes (charge de 36 M€ en 2024, qui ...
- Research Department
INFORME DIARIO 21 NOVIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: SANTANDER. Continúa la cautela por la geopolítica Pese al buen arranque de las bolsas europeas, las ganancias se fueron diluyendo hasta terminar con tímidas caídas, pendientes de la tensión en Ucrania y los resultados de Nvidia (que publicó buenos resultados con el mercado ya cerrado aunque recortó por dudas con respecto al 4T). Así, dentro del STOXX 600, R.Básicos y Farma (por segundo día consecutivo) lideraron las ganancias, frente a Autos (que ...
- Felix Fischer
- Ian Wong
- Jayanth Kandalam
- Si Yong Ng
- Tanvi Arora
- Carole Braudeau
Credit Morning 11/20/2024
Grifols: the board considers that Brookfield’s indicative price undervalues the company Teva: S&P upgrades the rating to BB/positive from BB/positiveElior: Results recovered in 2023-24, exceeding expectations. Debt reduction is making headway as planned.Tereos: Sharp decline in EBITDA in Q2 24/25. The financial position is stable thanks to the generation of FCF.>...
- Emmanuel Matot
ODDO BHF Small & MIDCAP MORNING NEWS - 11/20/2024
Efforts to revitalise the five brands that make up the Lanvin Group are under way and should pay off in the medium term. However, at this stage of development (critical mass not yet achieved for some brands, negative profitability and cash burn) and in a consumer environment that does not yet point to a rebound, we prefer to remain cautious on the share. We are initiating coverage with a Neutral rating, with a target price of $ 1.80, based on a DCF valuation. - ...
- Carole Braudeau
Morning Crédit 20/11/2024
Grifols : le conseil d’administration estime que le prix indicatif proposé par Brookfield sous-évalue la sociétéTeva: S&P upgrades the rating to BB/positive from BB/positiveElior: les résultats se sont redressés 2023/24, dépassant les attentes. Le désendettement progresse comme prévu.Tereos : fort repli de l'EBITDA au T2 24/25. La situation financière est stable grâce à la génération de FCF.>...
- Emmanuel Matot
ODDO BHF Small & MIDCAP MORNING NEWS - 20/11/2024
Les efforts de redynamisation sont en cours pour les 5 marques qui constituent Lanvin Group et devraient porter leurs fruits à moyen terme. Toutefois, à ce stade de développement (taille critique encore non atteinte sur certaines marques, rentabilité négative et consommation de cash) et dans un environnement de consommation n’indiquant pas encore de rebond, nous préférons rester encore prudents sur le titre. Nous initions à Neutre, avec un OC à 1.8 $ résultant d’une valorisation par D...
- Johanna Jourdain
Elior : FY 2023-24 results mixed (better on EBIT but a miss on net inc...
>FY 2023-24 results above at the EBIT level but a miss on net income - Elior reported FY 2023-24 results (October 2023 to September 2024) that beat expectations at the EBIT level but missed on net income. Sales were € 6,053m, in line with the consensus at € 6,043m and up 16% on a reported basis. Organic growth was 5.1%, broadly in line with the consensus at 5.3% (ODDO BHF at 5.4%, guidance of +4-5%). We note a deterioration in the retention rate to 91.2% (vs 92.0% in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.